Prelude Therapeutics
PRLD
61 hedge funds and large institutions have $41M invested in Prelude Therapeutics in 2024 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 26 increasing their positions, 12 reducing their positions, and 16 closing their positions.
117% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 12
8.55% less ownership
Funds ownership: 84.79% → 76.24% (-8.5%)
13% less funds holding
Funds holding: 70 → 61 (-9)
45% less capital invested
Capital invested by funds: $74M → $41M (-$33M)
56% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$652K |
| 2 |
Renaissance Technologies
New York
|
+$581K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$546K |
| 4 |
Millennium Management
New York
|
+$401K |
| 5 |
Two Sigma Advisers
New York
|
+$335K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$7.8M |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
-$1.91M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$1.84M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$583K |
| 5 |
Walleye Capital
New York
|
-$172K |
PRLD Hedge Fund Activity: Q4 2024 in Review
61 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q4 2024, worth a combined $41M — down 45% from $74M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of PRLD and 7 opened new positions — a net loss of 9 holders — while 12 trimmed existing stakes and 26 added.
The largest buyer was Jacobs Levy Equity Management, adding an estimated $652K. The largest seller was Deerfield Management, exiting entirely with an estimated $7.8M sold.
- 61 institutional investors held Prelude Therapeutics (PRLD) as of Q4 2024, down from 70 in Q3 2024.
- Funds reported $41M of Prelude Therapeutics stock for Q4 2024, down 45% quarter-over-quarter.
- 7 funds opened new Prelude Therapeutics positions in Q4 2024 and 16 closed out, a net change of -9 holders.
- The largest Prelude Therapeutics buyer in Q4 2024 was Jacobs Levy Equity Management, an estimated $652K added.
- The largest Prelude Therapeutics seller in Q4 2024 was Deerfield Management, an estimated $7.8M sold.
Based on aggregated 13F filings for Q4 2024.